Literature DB >> 7060328

Aspirin blocks nicotinic acid-induced flushing.

J K Wilkin, O Wilkin, R Kapp, R Donachie, M E Chernosky, J Buckner.   

Abstract

Nicotinic acid flushing after placebo and 975-mg oral doses of aspirin was assessed in 29 normal subjects over a range of nicotinic acid doses. Intensity of flushing was assessed by the change in malar thermal circulation index (delta MTCI). Aspirin pretreatment resulted in smaller delta MTCIs at the higher doses of nicotinic acid. At the lower doses the change in the index after pretreatments with both aspirin and placebo remained low, suggesting that very little flushing was provoked by these doses. These results are compatible with the proposed mediation by prostaglandins of the nicotinic acid-induced flush. According to the delta MCTI method, flushing is quantitatively characterized as a nonquantal, dose-response reaction of variable intensity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7060328     DOI: 10.1038/clpt.1982.63

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Effect of niacin on the choroidal circulation of patients with age related macular degeneration.

Authors:  T I Metelitsina; J E Grunwald; J C DuPont; G-S Ying
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

2.  Clinical and laboratory responses to niceritrol in the treatment of hypercholesterolaemia.

Authors:  L D Curtis; J P Reckless; A F Winder; D J Betteridge
Journal:  Postgrad Med J       Date:  1988-09       Impact factor: 2.401

Review 3.  Niacin: another look at an underutilized lipid-lowering medication.

Authors:  Julia C Creider; Robert A Hegele; Tisha R Joy
Journal:  Nat Rev Endocrinol       Date:  2012-02-21       Impact factor: 43.330

Review 4.  Niacin: the evidence, clinical use, and future directions.

Authors:  Todd C Villines; Andrew S Kim; Rosco S Gore; Allen J Taylor
Journal:  Curr Atheroscler Rep       Date:  2012-02       Impact factor: 5.113

5.  Effect of oral niacin on central retinal vein occlusion.

Authors:  Michael W Gaynon; Yannis M Paulus; Ehsan Rahimy; Janet L Alexander; Sam E Mansour
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-04       Impact factor: 3.117

6.  Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics.

Authors:  Richard L Dunbar; Harsh Goel; Sony Tuteja; Wen-Liang Song; Grace Nathanson; Zeeshan Babar; Dusanka Lalic; Joel M Gelfand; Daniel J Rader; Gary L Grove
Journal:  J Lipid Res       Date:  2017-01-23       Impact factor: 5.922

7.  Niacin sensitivity and the arachidonic acid pathway in schizophrenia.

Authors:  Erik Messamore; William F Hoffman; Jeffrey K Yao
Journal:  Schizophr Res       Date:  2010-04-24       Impact factor: 4.939

Review 8.  Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.

Authors:  Klaus G Parhofer
Journal:  Vasc Health Risk Manag       Date:  2009-11-16

9.  Effects of aspirin upon the flushing reaction induced by niceritrol.

Authors:  R H Jay; A C Dickson; D J Betteridge
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

Review 10.  Mechanisms of flushing due to niacin and abolition of these effects.

Authors:  Aditya Sood; Rohit Arora
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-11       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.